Table 2 Clinical characteristics by local recurrence versus non local recurrence

No. of patients

144

17

161

Tumor size T1/T2

86/58 (67%/33%)

12/5 (71%/29%)

0.46

98/63 (61%/39%)

pN0/pN+

83/61 (58%/42%)

7/10 (41%/59%)

0.19

90/71 (56%/44%)

Grade I/II/III

41/47/56 (28%/33%/39%)

2/7/8 (12%/41%/47%)

0.16

43/54/64 (27/33/40%)

Age <40 years

28 (19%)

7 (41%)

0.074

35

Median follow-up (years)

7.68

9.31

0.014

7.69

Metastasis

40 (28%)

9 (53%)

0.004

49 (30%)

Chemotherapy

50 (35%)

8 (47%)

0.291

58 (36%)

Hormonal therapy

16 (11%)

2 (12%)

0.86

18 (11%)

ER⁺/ER^-

109/35 (76%/24%)

12/5 (71%/29%)

0.42

121/40 (75%/25%)

Median RT dose (Gy)

50

50

0.47

50

Median boost dose (Gy)

15

15

0.22

15

Boost, yes/no

131/13 (91%/9%)

13/4 (76%/24%)

0.075

144/17 (89%/11%)

Margins infiltrating carcinoma^b

129, 6, 9 (90%, 4%, 6%)

16, 1, 0 (94%, 6%, 0%)

0.365

145, 7, 9 (90%, 4%, 6%)

Margins DCIS^c

49, 76, 9, 10 (34%, 53%, 6%, 7%)

3, 13, 1, 0 (18%, 76%, 6%, 0%)

0.65

52, 89, 10, 10 (33%, 55%, 6%, 6%)